Seres Therapeutics, Inc. is a clinical-stage company focused on developing biotherapeutics for serious diseases. Its pipeline includes SER-155, an investigational oral live biotherapeutic designed to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections and other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a live biotherapeutic product candidate optimized to treat disruptions in the GI microbiome and improve GI mucosal barrier integrity by inhibiting inflammatory bacteria and associated metabolites, and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream infections and spontaneous bacterial peritonitis in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Incorporated in 2010, it is headquartered in Cambridge, Massachusetts.
USA